Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-16-091777
Filing Date
2016-03-31
Accepted
2016-03-31 10:03:02
Documents
8
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 20-F v435600_20f.htm 20-F 1663848
2 EXHIBIT 23.1 v435600_ex23-1.htm EX-23.1 2309
3 EXHIBIT 23.2 v435600_ex23-2.htm EX-23.2 2733
4 EXHIBIT 31.1 v435600_ex31-1.htm EX-31.1 9610
5 EXHIBIT 31.2 v435600_ex31-2.htm EX-31.2 9590
6 EXHIBIT 32.1 v435600_ex32-1.htm EX-32.1 4547
7 GRAPHIC tpg23.jpg GRAPHIC 56312
8 GRAPHIC tlogo.jpg GRAPHIC 4361
  Complete submission text file 0001144204-16-091777.txt   1777456
Mailing Address 85 MEDINAT HAYEHUDIM ST. PITUACH, PO BOX 4033 HERZLIYA L3 46140
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

EIN.: 000000000
Type: 20-F | Act: 34 | File No.: 001-36000 | Film No.: 161541856
SIC: 2834 Pharmaceutical Preparations